FDA Approves Ibrutinib/Rituximab for Waldenstrom Macroglobulinemia

August 27, 2018 – The FDA has approved ibrutinib for use in combination with rituximab as a treatment option across all lines of therapy for patients with Waldenström macroglobulinemia. The approval is based on findings from the phase III iNNOVATE (PCYC-1127) trial presented at the 2018 ASCO Annual Meeting and published in the New England Journal of Medicine.1,2 In the study the ibrutinib/rituximab combination lowered the risk of disease progression or … (leggi tutto)